Clinical validation of a novel metagenomic nanopore sequencing method for detecting viral respiratory pathogens

Nicholas D. Sanderson*[#][1,2], Kate Dingle[#][1,2], Katie M.V. Hopkins[1,2], Ali Vaughan[1,2], Matthew Colpus[2], Melody Parker[1,2], Elisabeth Vilde Dietz[2], Jessica Gentry[3], Anita Justice[3], Sarah Oakley[3], Lucinda Barrett[3], T. Phuong Quan[1,2,4], Nicole Stoesser[1,2,3,4], David W. Eyre[1,2,4], Philip Bejon[1,2,3], Ann Sarah Walker†[1,2,4], Bernadette C. Young†[1,2,3]

[#] contribution considered equal

[†] contribution considered equal

Affiliations

[1] NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK

[2] Modernising Medical Microbiology Unit, Nuffield Department of Medicine, University of Oxford, Oxford, UK

[3] Oxford University Hospitals NHS Foundation Trust, Oxford, UK

[4] NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at University of Oxford, Oxford, UK

Contributions

Conception or design; N.D.S, K.D, D.E, A.S.W, B.C.Y. Acquisition, analysis or interpretation of data; N.D.S, K.D, K.M.V.H, M.C, M.P, V.D, T.P.Q, N.S., D.E, P.B., A.S.W, B.C.Y. Drafted the work or substantively revised it: N.D.S, A.S.W, B.C.Y.

Corresponding author

22   *Correspondence to: nicholas.sanderson@ndm.ox.ac.uk

23   https://orcid.org/0000-0001-6370-1961

Abstract

Clinical metagenomics (CMg) offers high-throughput respiratory pathogen detection with a wider

range than targeted, probe-dependent diagnostics. We optimised a long-read sequencing workflow to

detect RNA viruses in nasopharyngeal swabs. We derived quality control (QC) criteria and diagnostic

thresholds against a gold standard comprising 23 pathogen targets detected by routine multiplex PCR.

We validated this workflow using 344 prospectively collected respiratory samples submitted for

routine testing. Using pre-defined QC and positivity criteria, the workflow's sensitivity versus PCR

was 51% (95%CI: 45%-57%) (133/260 positive targets detected) (ranging from 19%-85% across

pathogens with >20 gold-standard detections), and specificity 99.8% (95%CI: 99.6%-99.9%)

(3836/3845 negative targets not detected). Sensitivity improved to 58% using post-hoc optimised

thresholds, 61% only considering RNA pathogens, 70% excluding rhinovirus/enterovirus and 83%

excluding samples with qPCR Ct values ≥35. Multiplexed nanopore sequencing costs were

£112GBP/sample, however read crossover from multiplex sequencing contributed importantly to

false-positives. Although CMg has substantial diagnostic potential, this validation study demonstrates

the technical limitations of current metagenomic sequencing methods applied to viral detection in

upper respiratory tract samples with high host and low pathogen biomass: its higher reliability at

higher viral loads demonstrates the importance of identifying the most appropriate use cases to

maximise its utility.

Introduction

Respiratory tract infections remain a leading cause of illness with substantial impact on health care

systems[1]. Diagnostic testing in respiratory infections continues to be a major challenge for medical

microbiology[2–5]. A wide range of pathogens can cause respiratory tract infection, and while much of

the burden is caused by different viral pathogens, co-infections are common[6]. Still, most routine

diagnostic testing remains targeted[7]. Targets may include single pathogens (eg urinary Legionella

antigen), or be configured as 'syndromic' panels which test for a pre-defined array of pathogens[8–10].

While offering high sensitivity, and convenient workflows with minimal hands-on time, these assays

are constrained in scope to target species or serogroups[11,12]. Further, molecular tests may be vulnerable

to naturally occurring variations in the assay target (such as mutations altering primer binding regions

or antigen conformation)[13,14], and may lack ability to distinguish between important species (eg.

rhinovirus vs enterovirus) or subtypes. Ideal pathogen workflows would be robust to sequence

changes, including the target failures which can compromise PCR assays (such as the S-gene drop out

seen with evolving lineages of SARS-CoV-2)[15], and would not be limited to a list of target species.

Clinical metagenomics (CMg) has emerged as a promising modality to deliver rapid, untargeted and

simultaneous pathogen detection directly from clinical samples. Early adoption of this approach has

focussed particularly on critical care settings and the analysis of lower respiratory tract specimens such

as bronchoalveolar lavage (BAL)[16,17]. In critically ill patients, a broad differential diagnosis,

preponderance of bacterial infections and extensive antibiotic exposure may give CMg an advantage

against conventional diagnostics in terms of speed and yield[18]. Studies reporting CMg use in critical

care have focussed on bacterial detection and antimicrobial resistance profiling[19,20], but its flexibility

means it could be extended to include viral and fungal infections[21].

Routinely applying a respiratory CMg workflow in broader patient groups has technical challenges.

Specimens containing high host but limited pathogen biomass (such as nose/throat swabs) can make

accurate detection of signal from noise particularly difficult, particularly as some CMg workflows

count only a single pathogen read as detection[22]. Human nucleic acid dominates many samples, though

host depletion strategies can improve relative pathogen abundance[23]. The human sequence dominance

has been overcome by short-read sequencing to very high depths, but at a relatively high per sample

cost: a well validated workflow incurred sequencing costs of $260USD per test (estimated £198GBP

on 2025 average exchange rate)[24]. Pathogen enrichment strategies include targeted pathogen baits,

targeted amplification of preserved motifs (such as bacterial detection with 16s rRNA), or untargeted

amplification (sequence independent, single primer amplification (SISPA), or phi29 polymerase)[25,26].

These strategies can improve sensitivity but potentially introduce detection bias, especially where

amplification is targeted, and increase the cost of processing. The introduction of contaminating

material from reagents or the environment, and barcode/index misclassification, can all produce false

positive results[27]. Distinguishing true detection of low pathogen levels from artefact relies on the use

of well-constructed controls as well as optimised laboratory practices and bioinformatic sequence data

processing[28]. Other approaches include multidisciplinary review of results for interpretation, but this is

costly and may limit an assay's reproducibility and throughput[17]. Hence, there are multiple technical

challenges for metagenomic tests. Importantly, whist ultimately the goal is agnostic detection of any

pathogen, validation of sensitivity and specificity against known pathogen targets is necessary (but not

sufficient) before using any metagenomic assay untargeted.

In order to scale CMg in routine care, it will not be cost-effective to depend on high read numbers, and

the extent to which transparent and robust bioinformatic criteria can be set and consistently applied for

the detection of known, common pathogens is currently unclear. We therefore present an end-to-end

clinical validation of a metagenomic workflow for enhanced detection of common RNA respiratory

viruses from naso-pharyngeal samples. The workflow uses a combination of low-cost virus

enrichment and non-target depletion approaches, embedding positive and negative controls, prior to a

modernised SISPA step. Samples are sequenced on the Oxford Nanopore Technologies (ONT)

platform. As the necessary first step, a specific set of 23 known pathogens and pathogen subtypes

comprising the diagnostic targets of the most commonly used commercial multiplex PCR platform

were identified by mapping reads to a curated reference genome database. We used a derivation

sample set to develop bioinformatic thresholds for pathogen identification, and then evaluated their

performance in an independent validation set, using commercial multiplex PCR assays as the gold

standard and within laboratory and bioinformatic quality control frameworks, including delineation of

analytic sensitivity and specificity.

Results

Respiratory samples for pathogen detection

The study used nose and/or throat samples submitted for routine clinical microbiology PCR testing, which was done on one of three platforms: two four-target assays (Alinity Resp-4-plex assay (Abbott), or Xpert Xpress CoV-2/Flu/RSV plus (Cepheid), or the 23-target assay BIOFIRE FilmArray Respiratory 2.1 panel (Biomerieux) (**Table S1**). The four-target assays (covering influenza A/B, respiratory syncytial virus (RSV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)) were performed routinely, while 23-target PCR testing was undertaken for samples from immunocompromised patients or those admitted to critical care. Surplus material from samples with a positive result on any platform were prospectively collected, along with a smaller number of temporally matched samples testing negative by FilmArray (**Table 1(a)).**

In total 382 respiratory samples were retrieved, divided temporally into separate sample sets: a) a derivation (n=38 clinical samples, tested repeatedly to produce n=104 individual sequences); and b) a validation set (n=344 clinical samples, each tested once to produce n=344 individual sequences). Because each sample had a positive or negative result from PCR gold standard testing for multiple pathogens which may or may not be detected by metagenomic sequencing, each sample contributed multiple observations to the analysis (i.e. each pathogen tested for using gold standard PCR contributed one observation with the outcome being presence or absence of that pathogen on sequencing results). The derivation set was used to define bioinformatic criteria for pathogen detection by sequencing and thresholds for quality control (QC) for both positive and negative controls, criteria which were then fixed and tested using the validation set, with all validation assays and sequencing conducted by laboratory staff blinded to validation study results throughout.

Sample preparation and sequencing followed a single optimised laboratory method in the validation set (**Figure 1, Methods**) (derivation sample preparation and sequencing used a similar near final method, see **Methods**). Validation samples were sequenced in batches with batch positive and negative controls, and internal amplification controls in each sample (**Table 2**, **Methods**). Samples were positive for a range of pathogens by PCR, dominated by influenza A, RSV, human rhinovirus/enterovirus (HRE) and SARS-CoV-2, other RNA viruses and a small number of DNA viruses and bacteria (**Figure 2**). These were randomly mixed across sequencing runs for both

127   derivation and validation sets. Samples came from patients with a wide range of ages (**Table 1(b)**) and

128   a range of inpatient and emergency locations.

Derivation Set: Defining thresholds for quality control

130   The derivation set included 104 sequencing results from 38 samples, all with at least one pathogen

131   detected on multiplex PCR testing (**Table 1**, **Figure 2**). Although the CMg workflow was focussed on

132   RNA virus detection, we evaluated its performance with respect to all pathogens included in the

133   FilmArray panel. Total data obtained per run and reads per sample (**Figure S1**) were used to set

134   heuristic thresholds for sequencing run quality checks (**Table 2**).

Derivation Set: Improved base-calling accuracy and read thresholds reduce

false-positives from barcode crossover

To test the ability of the CMg workflow to reproduce results from commercial platforms at the highest

possible resolution[29], pathogen detection was based on mapping reads to a curated database of known

respiratory pathogen genome sequences using minimap2 (**Methods**). In the derivation set the median

(IQR) length of all reads was 292bp (278-308bp) (**Table 1**). Using standard high accuracy base-calling

(HAC) in the derivation set initially, we identified evidence of barcode crossover leading to

sequencing reads being mis-attributed to another sample within a multiplexed pool, alongside broader

issues with demultiplexing (**Figure S2**). For example, a median (IQR) 0.1% (0.08%-0.11%) of reads

were assigned to barcodes not used in the library preparation, and 21% (17%-32%) barcode sequences

identified remained unclassified. Among the derivation set, 65/104 (62%) sequences had reads

mapping to the pathogen identified by PCR in that sample; but 63/104 (61%) sequences also had one

or more reads mapping to a pathogen for which the sample tested negative by PCR. Use of the super

accuracy base-calling (SUP) model improved but did not eliminate this problem, reducing the median

reads assigned to unused barcodes to 0.01% (0.01%-0.013%), and resulting in 64/104 (62%)

sequences with reads mapping to the pathogen identified by routine PCR testing and 34/104 (33%)

with one or more reads mapping to a pathogen for which the sample was PCR-negative before any

diagnostic thresholds were implemented. All these 34 initial false-positives in the derivation set

occurred on sequencing runs which included another PCR-positive sample with a high number of

reads for the pathogen detected, and were based on single read in 12/104 (12%) sequences. We

therefore implemented a threshold of "≥2 reads " for target pathogen detection (**Table 2**), resulting in

56/104 (54%) derivation set sequences with ≥2 reads mapped to the pathogen identified by routine

PCR testing and 18/104 (17%) with ≥2 reads mapping to a pathogen for which the sample was PCR-

negative.

This "≥2 reads" quality threshold was also then applied to sequencing batch positive and negative

controls, and internal sample controls (**Table 2**). MS2 was added to each sample as a control of

nucleic acid extraction and subsequent cDNA synthesis and SISPA. Three viruses were added to each

sample following nucleic acid extraction as internal controls of cDNA synthesis and SISPA. Each

batch of 16 samples was accompanied by a positive amplification control consisting of the same 3

spiked-in viruses a negative (no template) control. 2/6 (33%) derivation sequencing runs, containing

24/104 (23%) sequences, failed sequencing batch negative control thresholds(i.e. had ≥2 reads

mapping to MS2 or one the three viral internal amplification controls). In those runs that passed

sequencing batch controls, 19/80 (24%) sequences failed internal controls, of which 8/19 (42%) failed

to detect two internal control viruses and 11/19 (58%) failed to detect all three internal control viruses

(**Figure 3C**). In total 61/104 (59%) derivation set sequences successfully passed the negative and

positive batch control and internal controls and were used to subsequently establish bioinformatic

thresholds for pathogen detection.

Derivation Set: Defining bioinformatic thresholds for pathogen detection

Within the 61 sequences in the derivation set passing QC, 67 pathogen targets were detected by

routine PCR (i.e. gold standard positives), and 1154 pathogen targets were not detected by PCR (i.e.

gold standard negatives), given the variable numbers of pathogen targets tested per sample, depending

on the multiplex PCR assay used (**Table 1**). We evaluated 28 different bioinformatic metrics against

true-positives and true-negatives to optimise detection (**Tables S2**, **S3**), individually and in

combination. Many individual metrics and combinations of metrics had very similar performance

(**Tables S2, S3, S4**), and were highly collinear (**Figure S3**). Maximising Youden's index and taking

into account different sequencing aspects (**Table S2**), we chose a final combination of three separate

metrics (details in **Methods**), encompassing coverage breadth, depth and the proportion of mapped

reads, to address known sources of error in metagenomics[30,31]. Specifically, a pathogen was defined as

detected in the sequence read data if a) the percentage of the reference genome with coverage of at

least 1 read was >0.25%, or b) the mean read depth (truncated at a maximum of 10 at all positions)

across the entire genome (denoted "area under the genome") was >0.003, or c) the number of reads in

the sample mapping to the target reference genome as a percentage of reads on the run mapping to any

pathogen reference genome >0.006% (**Table 2**).

Combining these three "OR" criteria with an additional "AND" criterion for ≥2 target pathogen reads

led to 28/1929 false-positives including all sequenced samples in the derivation set (including those

not passing batch/internal QC control), and 4/1154 false-positives after restricting to sequenced

samples that passed QC checks (run, batch and internal). False-positives had proportionately lower

"area under the genome" for the percentage of reads in the sample mapping to the target reference

genome as a percentage of reads on the run mapping to any pathogen reference genome (**Figure 4A**).

We therefore added a third "AND" "ratio criterion" for positivity, specifically that the ratio between

these criteria should be >0.1 (**Table 2,** red line on **Figure 4A**).

Hence the final pathogen detection criteria determined on the derivation set were: percentage of

reference genome with at least 1 read >0.25% OR "area under the genome" >0.003 OR percentage of

reads mapping to reference genome>0.006%) AND >2 target pathogen reads AND "ratio

criterion">0.1 (**Table 2**).

43/67 (64%) PCR-positives in the derivation set were detected by these three criteria (**Figure 3E**): of

the 24 PCR-positives classified as negative, 18 (27% of the total) had no reads mapped to the target

pathogen, and 6 (9%) had only a single read mapped to the target pathogen (failed the ≥2 reads

threshold). 1151/1154 (99.7%) of the pathogens tested for, but not detected by multiplex PCR, were

not detected by sequencing. The three false-positive target detections in 2 of 38 original samples were

SARS-CoV2 (two reads) and influenza A, further subtyped as H1-2009 (five reads; two target

detections).

Validation Set: Diagnostic performance

To validate the performance of the metagenomic workflow with the derived thresholds, we used 344

independent respiratory samples with known multiplex PCR results (199 tested for 23 targets with

FilmArray, 136 tested for four targets with Xpert, and 9 tested for four targets with Resp-4-Plex,

Table 1). These were extracted in 22 batches and sequenced on 11 runs (**Figure 5**). 2/22 (9%) batches

(containing 31/344 (9%) samples) failed batch QC, with one amplification control sample failing all

three internal control viruses (<2 mapped reads), and one batch amplification control sample failing

due to detection of reads from a target pathogen (**Figure 5**). 39 samples failed internal quality checks

of extraction or amplification, 38/39 (97%) failing to detect MS2 extraction and amplification control;

in addition, 2/39 (8%) did not detect two internal control viruses and 9/39 (23%) failed to detect any

internal control viruses (**Figure 3D**). Overall, 273/344 (79%) respiratory samples in the validation set

passed negative and positive control QC criteria.

In these 273 samples passing QC, there were 260 pathogen target detections by multiplex PCR (i.e. the

gold standard), with 212 (78%) samples positive for a single pathogen, 21 (8%) positive for two

pathogen targets (42 in total), 2 (1%) positive for 3 pathogen targets (6 in total). Within these

detections, six (2%) samples were positive for influenza A with additional detection of the H1 subtype

target (counted as 2 detections each, see Methods) (**Table 1**). 38/273 (14%) samples passing QC were

PCR-negative for all pathogens.

133/260 (51%, 95%CI: 45-57%) PCR-positive results (i.e. gold standard positives) were also detected

by sequencing (**Table 3**, **Figures 3D, 4B**). Of samples with multiple pathogens found by PCR, 1/21

(4.8%) had two pathogens detected by sequencing, while 0/2 (0%) had three pathogen detections by

sequencing. Within the 127 false negative results, 89 (34% of the 260 total results) had no reads

mapped to the target pathogen, 17 (7% of the total) had only a single mapped read and therefore fell

below the threshold designed to minimise barcode crossover, 20 (8%) had ≥2 reads and met at least

one of the three main criteria but failed the ratio criteria (as defined in **Table 2**), and 1 (0.4%) had ≥2

mapped reads and achieved the ratio criteria but did not meet any of the three main criteria (**Figures**

3D, 4B).

3901/3910 (99.8%) targets negative by PCR (as tested in the original assays, see **Methods**) were also

not detected from sequencing (**Table 3**); 38 samples were PCR negative for all pathogens, of which 36

(95%) were also negative by sequencing. There were nine false-positive pathogen detections by

sequencing, all potentially attributable to barcode crossover (**Figure 4B**): these were: a) four

detections of SARS-CoV2 with two reads each, all on a single run that contained a sample with a very

early cycle detection of SARS-CoV2 on PCR (Resp-4-Plex Cn 13.54; 51,158 reads); b) four detections

of coronaviruses (3 HCoV-HKU1, 1 HCoV-OC43) from one run with 2-38 reads (Run 11) that

included a sample with 33,347 reads mapping to HCoV-HKU1 (PCR done by FilmArray, hence

lacking a Cn/Ct result); and a metapneumovirus from a run with 79 reads that also included two other

positive metapneumovirus samples with 48 and 810 reads (PCR also done by FilmArray).

The ratio criterion performed considerably less well in the validation set compared with the derivation

set, resulting in 20 false negatives solely from applying this criterion (**Figures 3D, 4B**). We compared

the main and ratio criteria (**Table 2**) with an alternative criterion which had relatively similar

performance to these criteria in the derivation set (**Tables S2, S4**). This criterion confirmed detection

if the number of reads in the sample mapping to the target reference genome as a percentage of reads

on the run mapping to the specific target genome (rather than all reference genomes) was >0.037%.

Replacing the main and ratio criteria with this alternative criterion (but retaining the ≥2 read criterion)

increased the number of samples passing batch controls from 260 to 274, increased sensitivity to 58%

(95% CI 52-64%; 159/274), and improved specificity to 99.9% (95% CI 99.8-100%; 4015/4017) with

only 2 false positive detections (**Table 3, Figure S4**), the metapneumovirus and coronavirus OC43

detections.

Performance by pathogen

While overall sensitivity using the criteria from the derivation set was 51%, assay performance varied

substantially by pathogen. Sequencing detected fourteen different RNA viruses in samples passing

QC, but no bacteria or DNA viruses. One *Chlamydia pneumoniae* was detected (3 reads) in a sample

whose positive controls failed (**Figure 6A**). Of the pathogen targets with more than 20 PCR-positive

results, sensitivities from highest to lowest were: RSV 85% (95% CI: 75-95%); SARS-CoV-2 65%

(95% CI: 53-78%); influenza A 58% (95% CI: 40-75%), and rhinovirus/enterovirus 19% (95% CI: 8-

29%) (**Figure 6B**) using the main criteria, with small improvements using the alternative criteria for

all except SARS-CoV-2.

The sample workflow was designed to maximise RNA pathogen detection. Excluding DNA pathogen

targets (adenovirus and bacterial species) from the evaluation increased sensitivity modestly to 61%

(159/260) (95% CI 55-67%) (**Table 3**). The clinical significance of some low viral level results for

enterovirus and rhinovirus is unclear[32] and in our study qPCR results frequently indicated low viral

loads (**Figure S5B**). Removing these two targets increased overall sensitivity using the alternative

criteria to 70% (145/207) (95% CI 63%-76%) (**Table 3**).

CMg provides greater taxonomic resolution than multiplex PCR

271 The sequencing workflow classified pathogens at higher resolution than multiplex PCR methods. Ten

272 rhinovirus/enterovirus FilmArray positive samples were further identified as Rhinovirus B3 (n=6),

273 Rhinovirus C (n=1), Rhinovirus A89 (n=1), Enterovirus A (n=2). All 47 samples with RSV detected

274 on PCR were further identified as either RSV-A (n=25) or RSV-B (n=22).

Additional pathogen targets detected

We detected two additional pathogens using CMg sequencing of targets not assayed in the original

PCR test (i.e. samples originally tested for only 4 pathogens), in 2/111 (2%) samples. These two also

passed the alternative criteria and were not on runs with other strong positives, representing plausible

additional detection. Human rhinovirus/enterovirus (HRE) was detected in one RSV-positive sample,

with genome mapping revealing it to be human rhinovirus B3. Coronavirus OC43 was identified in

one sample with SARS-CoV-2 detected by PCR. In addition, 13 samples with influenza A detected on

PCR were able to be subtyped with sequencing: 12 as influenza A/H1-2009 and one as influenza

A/H3.

Performance by viral load (Cn,Ct) and other factors

PCR Cn/Ct values were reported from the original Resp-4-Plex/Xpert platforms for influenza, RSV

and SARS-CoV-2: these showed high correlation with Ct values ascertained separately by qPCR as

part of this study (**Figure S5A**), although study qPCR Ct values were 5-10 cycles higher than original

Cn/Ct values, potentially due to loss of material during processing and/or to the use of different assays.

Other pathogens show similar study qPCR Ct values across targets (Coronavirus HKU,

rhinovirus/enterovirus) where detected (**Figure S5B**). Study qPCR detection rates did not vary

substantially by pathogen (**Figure S5C**).

The number of mapped reads was strongly associated with Ct value, with samples with higher Ct

values generating fewer reads as expected, whether Ct was from the original Resp-4-Plex/Xpert assay

(not available for Filmarray) (**Figure 7A**) or from study qPCR (**Figure 7B**). A valid Ct value from the

study qPCR assay indicated nucleic acid was extracted during the lab protocol; sensitivity using the

alternative criteria for samples with any Ct value from the study qPCR assay increased to 75% (95%

CI, 68-81%) (**Table 3**). Restricting analysis further to those with a study qPCR Ct <35 (i.e. higher

viral loads) increased sensitivity using the alternative criteria to 83% (95% CI, 76-88%) (**Table 3**).

Sequencing assay cost

The sequencing and consumables costs were calculated based on multiplexing 32 clinical samples on

each sequencing run at £102.41/sample (**Table S6**). Sequencing platform costs were estimated

conservatively (assuming no other use of sequencing platform and amortising purchase cost over five

years) and added a further £9.61/sample. The analysis pipeline can be performed using GridION

onboard computing capacity, so no additional server or compute costs are required. In addition to

£112.02 of sequencing and infrastructure costs, there was 70 minutes of labour required per sample.

Discussion

Here, we have developed and assessed the performance of an end-to-end metagenomic workflow

which detects a range of RNA respiratory viruses. By applying stringent quality thresholds, we

achieved high specificity for both target pathogens (99.8%) and at an individual sample level (>96%).

Despite integrating pathogen amplification targeting the most common RNA viruses, sensitivity in a

large validation set was modest compared to multiplex PCR, ranging from 51% overall, and as high as

85% for RSV and as low as 19% for rhino/enterovirus using pre-defined detection criteria. This could

be improved modestly to 58% by using post-hoc exploratory alternative bioinformatic criteria, and

then further to 61% and 70% by again post-hoc excluding DNA pathogen targets and

enterovirus/rhinovirus respectively. By limiting our analysis to RNA viruses and samples with

pathogen detections on study qPCR with Ct <35 and using the alternative bioinformatic criteria,

sensitivity improved to 83%

We deliberately designed this ONT-based workflow to be achieved with a small footprint platform and

modest costs. The final reagent costs were £82GBP per sample, and reagent plus sequencing and

analysis platform costs are estimated at £112 per sample. This is achieved by multiplexing 32 clinical

samples across a single sequencing flow cell. CMg delivered multiple pathogen detections from a

single assay, and provided additional sub-typing and lineage information compared with PCR. While

cost compares favourably with extended multiplex PCR testing, the hands-on and labour time of the

assay was substantial, estimated at 70 minutes a sample, compared with a few minutes. The

sequencing cost of this assay was 45% less than the sequencing costs of an Illumina based respiratory

virus sequencing assay[24].

The ultimate goal of the assay was agnostic pathogen detection: however, a necessary first step was

the ability to reliably detect known targets. For this study, we therefore developed an initial simplified

mapping-based analysis pipeline for a panel of common and important respiratory pathogens tested in

routine microbiological laboratories, arguing mapping is the most sensitive approach to demonstrate

performance against known targets[29]. We validated this workflow on a prospective collection of

samples including 23 different PCR targets, representing a substantially broader validation than the 4-

8 targets validated in recent RNA virus CMg workflows[23,24]. Had the assay shown better performance

against known targets, the sequencing output generated could be further interrogated for novel and

emerging viruses with adaptations to the analysis pipeline reference database, or by sharing sequenced

reads with public health repositories[33].

The varying sensitivities obtained highlight the major challenges of direct from sample sequencing to

detect infections with high host and low pathogen biomass, as from nose and throat swabs rather than

the BALs most commonly used in ICU studies. Despite human cell depletion and RNA amplification,

34% of samples had no reads detected for the pathogen detected by routine PCR testing, and 20% of

gold-standard detections were not found by study qPCR following RNA extraction. At the same time,

imperfect barcode de-multiplexing of nanopore sequencing reads meant stringent thresholds were

needed to prevent false-positive detections. Reads were relatively short (~300bp), potentially due to

degradation of RNA genomes or short SISPA products. One recent CMg workflow required 3 non-

overlapping pathogen reads from a minimum of 5 million reads with short-read sequencing[24], while

another reported a single positive read on ONT sequencing as the threshold for virus detection[17]. For

the latter, sequencing was limited to 3 clinical samples per run, reducing the potential for cross-over,

but this increases per sample costs up to 2.7-fold, compared with testing 32 samples on a run.

One interesting question is why the assay performed relatively more poorly for rhinovirus/enterovirus

than other RNA viruses. We found that differences between study sequences and the references used

for mapping (**Table S5**) were greater for rhinovirus/enterovirus than other pathogens (**Figure S6**),

suggesting that alternative choice of reference strains might improve performance, and reflecting the

diversity of this pathogen group. The small genome size (~8kB vs ~13-30kb for other pathogen

targets) may also play a role in the low rate of detection (**Table S5**).

Our findings contrast with a recent UK study, which reported sensitivity for viral detection of 89%

(95%CI: 71-98) using respiratory CMg[21]. The differential performance is likely multifactorial. The

study by Alcolea-Medina et al was performed in patients in critical care, and >85% of viral detections

were from lower respiratory tract samples rather than the upper respiratory tract samples in this study.

For common respiratory viruses, lower respiratory tract samples show a higher viral load[34–36] than

nasopharyngeal samples. Moreover the low mass of host material in BAL samples allowed

investigators to omit depletion steps[21]. Finally, the study multiplexed ≤5 samples per sequencing run,

and 66% of included samples had no respiratory viruses detected by PCR testing. The lower capacity

for barcode or sample cross-over facilitated relaxed thresholds for sequencing detection, with a single

read only required for positivity[17].

For this specific analysis, we used a competitive mapping-based approach rather than a metagenomic

classifier because this allowed us to directly evaluate the performance of the workflow against a well-

defined gold standard of known pathogen targets. The mapping approach enabled fast curation and

masking of references and provided coverage metrics. However, the laboratory method is potentially

pathogen agnostic and therefore capable of detecting a wide range of known and unknown RNA

pathogens. A metagenomic classification tool, such as Kraken2[37] or Sylph[38], might be more

appropriate for the analysis if the method were to be used for pathogen surveillance: the performance

of an agnostic workflow would require further evaluation.

Our workflow was optimised for RNA pathogen detection, including two DNAse steps in the

laboratory methods: while reads mapping to DNA viruses and bacteria were detected they fell below

thresholds for detection in samples passing QC. This lack of sensitivity is likely due to the reliance on

detecting these pathogens via RNA transcripts. Nucleic acid extraction from clinical samples followed

by SISPA, as employed here, has a higher hands-on time and requires more specialised laboratory

practitioners than commercial kit-based multiplex-PCRs. These technical aspects and the modest

performance of the workflow mean that it will not replace currently available methods as it stands.

However, a metagenomic workflow using established laboratory methods and limited specialised

equipment could be a valuable asset to pandemic preparedness. RNA viruses are regarded as likely

candidates for emerging pathogens[39,40], and experience with MERS-CoV, SARS-CoV-2, highly

pathogenic avian influenza viruses and mpox virus have all highlighted the critical importance of

flexible diagnostic testing for pathogen detection and surveillance[41].

CMg undoubtedly has substantial diagnostic potential. However, with a laboratory workflow

optimised for RNA extraction, and bioinformatics optimised to stringent recognition of sample and

barcode cross-over, this study demonstrates the technical limitations of current nanopore metagenomic

sequencing applied to viral detection in upper respiratory tract samples with high host and low

pathogen biomass. Its higher reliability at higher viral loads demonstrates the importance of

identifying the most appropriate use cases to maximise its utility.

Methods
392

Sample collection
393

Nasopharyngeal samples collected with flocked swabs were placed in viral transport medium (VTM)

(UTM (Copan, Italy) or Sigma-Virocult (MWE, UK)) for routine clinical testing in the Microbiology

Laboratory, Oxford University Hospitals NHS Foundation Trust (Oxford, UK). Samples surplus to

clinical testing were retrieved. Inclusion criteria were: (i) nose and throat swabs, (ii) <7 days since

patient sampling, iii) pathogen detected at cycle threshold (Ct) or cycle number (Cn) value ≤30 for

Resp-4-Plex (Abbott, USA) and Xpert assays (Cepheid, USA) or sampled tested by BIOFIRE

FilmArray Respiratory 2.1 Panel (Biomerieux, France); the latter assay does not report a Ct value.

For the derivation set, samples were selected to cover the broadest range of pathogen detections by

PCR between March and July 2024. For the validation set, all positive samples meeting inclusion

criteria between October 2024 and March 2025 were retrieved, until a threshold of n=60 positives per

virus was reached (met for RSV, SARS-CoV-2 and human rhino/enterovirus). Approximately one

FilmArray negative sample was collected for every eight positives (by any method).

Clinical laboratory results were confirmed by retrieving data from the Laboratory Information

Management System. This included date collected, test type, pathogen result, and Cn/Ct value if

available.

Host Nucleic Acid Depletion and Virus Enrichment

Prior to RNA extraction, samples were pre-treated to reduce host nucleic acid and enrich for virus

particles. Swab-containing VTM was vortexed (30 seconds) and 1mL removed. Samples were

clarified by low speed centrifugation (3,200g, 30 min), pelleting intact human cells and debris. The

supernatant was transferred to a fresh lo-bind Eppendorf tube and free nucleic acid was digested using

M-SAN HQ (1000U) (ArcticZymes Technologies, Tromsø, Norway) with final $MgCl_2$ and Tris HCl

pH 8.0 concentrations adjusted to 10mM and incubation at 37°C for one hour. 500µl Intact Virus

Precipitation Reagent (Thermo Fisher Scientific, Waltham, MA, USA) was added, mixed by pipetting

and incubated overnight (4°C). Precipitants were collected by high speed centrifugation (13,200g, 30

min) and the supernatant was discarded. Phosphate buffered saline (PBS, Sigma Aldrich, USA) (20µl)

and MS2 extraction control (10µl) (Thermo Fisher Scientific) were added and the pellet resuspended

gently by pipetting, prior to RNA extraction.

RNA Extraction

Samples (30µl) were extracted using the Direct-zol RNA Microprep kit (Zymo Research) according to

the manufacturer instructions, including the optional on-column DNase treatment. RNA was eluted in

DEPC treated water (10µl) (Ambion, Thermo Fisher Scientific).

cDNA Synthesis and SISPA

First strand cDNA was synthesized using the Maxima H Minus 1st Strand cDNA synthesis kit with ds

DNase (Thermo Fisher Scientific), in a 20µl reaction volume, according to the manufacturer's

protocol, with the following modifications. Extracted RNA (8µl) was treated with DNAse, as

recommended, then spiked with three reverse transcription/amplification controls (1µl each,

containing approximately 10^4 genome copies each of Zika virus (ATCC-VR-1838DQ), murine

respirovirus (ATCC-VR-907DQ) and orthoreovirus (ATCC-VR-824DQ) (ATCC Manassas, Virginia,

USA). cDNA synthesis was primed randomly using the 3' terminal N_9 segment of custom

oligonucleotide primers (5'-GAT-GAT-AGT-AGG-GCT-TCG-TCA-CNN-NNN-NNN N-3';

Integrated DNA Technologies, Leuven, Belgium), final concentration 5µM. This incorporated the

SISPA primer sequence (5'-GAT-GAT-AGT-AGG-GCT-TCG TCA-3') into the first strand cDNA.

Following the recommended denaturation at 65°C for 5 min, 5x RT buffer and Maxima H minus

Enzyme Mix were added and primer annealing, reverse transcription and inactivation took place under

recommended conditions, 25°C for 10 min, 50°C for 30 min and 85°C for 5 min. Following reverse

transcription, cDNA fragments >~100 nucleotides were purified using SPRI beads (AMPure XP

beads, Beckman Coulter, Indianapolis, Indiana, USA) with two 70% ethanol washes and elution in

16µl DEPC-treated water (Ambion, Thermo Fisher Scientific). A 3µl cDNA aliquot was reserved for

separate study qPCR, and 11µl taken forward into second strand cDNA synthesis.

Second strand cDNA was synthesized using Sequenase™ V2.0 DNA Polymerase (Thermo Fisher

Scientific) and the same custom oligonucleotide primer, ((5'-GAT-GAT-AGT-AGG-GCT-TCG-TCA-

CNN-NNN-NNN N-3') randomly priming second strand synthesis and incorporating the SISPA

oligonucleotide primer. Reaction conditions were as described previously[42] comprising 11µl ss cDNA,

4µl 5x sequenase buffer, and 1µl oligonucleotide primer (40 µM). Samples were denatured at 97°C for

2 minutes and cooled to 4°C, then 1µl DTT (100mM), 1µl dNTPs (10mM) and 1.8 µl DEPC-treated

water were added, followed by incubation at 37°C for 8 minutes. A second identical incubation was

performed following the addition of 0.55µl sequenase dilution buffer and 0.2 µl Sequenase. Following

SPRI bead purification, dsDNA >100 bp was eluted in 22µl nuclease free water, 20µl of which was

amplified by SISPA PCR.

Each reaction (50µl) comprised 20µl ds cDNA, 5µl SISPA 1 oligonucleotide (5'-GAT-GAT-AGT-

AGG-GCT-TCG-TCA-3') (20 µM) and 25µl NEBNext® Ultra™ II Q5® Master Mix (New England

Biolabs, Ipswich, Massachusetts, USA). A no template negative control replacing cDNA with 20µl

DEPC-treated water was included at this stage. Amplification conditions were denaturation at 98°C for

30 seconds (1 cycle), followed by 30 cycles of denaturation at 98°C for 10 seconds, annealing 64°C

for 30 seconds, and extension 72°C for 1 min 30sec (30 cycles), and a final extension of 72°C for 2

minutes. A final SPRI beads purification was followed by elution in 15µl DEPC-treated water. The

amplification products were quantified by Qubit fluorometer using the dsDNA 1X BR Assay (Thermo

Fisher Scientific).

Library preparation and sequencing

Libraries were prepared according to the Rapid Sequencing V14-Amplicon Sequencing protocol from

ONT. Samples were sequenced using Rapid Barcoding Kit V14 (SQK-RBK114.96; ONT, Oxford,

UK) on R10.4.1 Flow Cells (ONT). A maximum of 36 samples were run on a single flow cell (32

clinical samples plus 4 positive/negative controls), and were run for 72 hours (with SUP base calling

enabled for the validation set).

qPCR of extracted cDNA

During cDNA synthesis, 3µl of single-stranded cDNA was reserved for quantification. Samples were

tested by qPCR assay targeting respiratory viruses detected on gold standard testing. Gold standard

RSV positive underwent separate qPCR for RSV-A and RSV-B. Gold standard HRE positives

underwent separate qPCR for enterovirus and rhinovirus. Due to limited cDNA availability, only 3

qPCR reactions were possible per sample. Samples with gold standard detection of >1 pathogen target

were prioritised for quantification with enterovirus and rhinovirus if HRE detected, followed by other

RNA viruses. Reaction conditions were as recommended by the manufacturer; 0.5µl TaqMan Microbe

Detection Assay (Thermo Fisher Scientific), 5µl TaqMan Fast Advanced Master Mix (Thermo Fisher

Scientific), 3.5µl H_2O and 1µl cDNA. Thermocycling was performed on the Quant Studio 5 PCR

machine with the following conditions; initial denaturation at 95°C for 20 seconds followed by 40

cycles of denaturation at 95°C for 1 second and annealing/extension at 60°C for 20 seconds. Standard

curves for quantification were generated by serially diluting True Mark Respiratory Panel 2.0

Amplification Control (Thermo Fisher Scientific) for a dilution range between 10^5 to 10^1 copies per

reaction. Standard curves were included on every qPCR reaction plate in triplicate. Quantification and

Ct values were determined using the Design and Analysis Software (Thermo Fisher Scientific) with

the "Quantification-TaqMan, Standard Curve" settings enabled.

Bioinformatic analysis

Raw ONT sequencing reads were basecalled on a GridION Mk1 with using Dorado (ONT) with the

current basecalling models at the time of sequencing: dna_r10.4.1_e8.2_400bps_hac@v4.3.0

(derivation set) or dna_r10.4.1_e8.2_400bps_sup@v4.3.0 (validation set). The derivation set ONT

sequences were subsequently basecalled again with the then current standalone model

dna_r10.4.1_e8.2_400bps_sup@v5.0.0 model and hardware (Nvidia RTX2080 GPU and Intel(R)

Xeon(R) Gold 5217 CPU @ 3.00GHz). It was not possible to re-call the validation set with this model

as the ONT output data was changed in July 2025 and the relevant pod5 files were not retained by

default.

Human host reads were filtered from the output fastq files before downstream analysis using kraken2

and the k2_pluspf_20240605 database (https://benlangmead.github.io/aws-indexes/k2). Further read

removal was performed using Deacon[43] with default settings before uploading to the ENA (project

number PRJEB102181).

The analysis workflow is provided on https://github.com/oxfordmmm/AD_analysis (v1.0). Read and

base numbers for each run and sample were calculated with SeqKit[44] v2.9.0. SISPA primers were

identified with BLASTn[45] v2.16.0+ (using parameters: -task blastn-short, word_size 7, gapopen 2,

max_target_seqs 10000000) and trimmed using the trim_primer.py script. Reads with more than 10

SISPA primers were removed before mapping. Reads were mapped using minimap2[46] v2.22-r1101

(using parameters: -ax map-ont -N 1000) to a curated composite reference fasta file including

representative genomes from a range of respiratory viral and bacterial pathogens (**Table S5**). Due to

non-specific mapping to the larger genomes (**Figure S6**), reads mapping to the bacterial genomes with

a mapQ score <40 were excluded. This was not applied to the reads mapping to the viral genomes.

We considered 28 potential bioinformatic metrics created from mapping the raw sequencing reads to

the composite references in samples passing QC in the derivation set (**Tables S2, S3**). Sequencing

coverage metrics used for species classification were calculated using samtools[47] v1.21 and the

coverageStats.py script. Metrics considered covered the following aspects

•   Coverage: at 1x, 3x, 5x or 10x depth, in absolute number of bases and as a percentage of

513   reference length (ie normalised)

• Read-depth coverage across the whole genome ("area under the genome") and divided by the

reference length: at overall, and truncating read depth to 5x or 10x to reduce the impact of

mis-mapped spikes of coverage

• Mean read-depth coverage across the genome with read depth at least one, excluding from the

denominator regions with no coverage, overall and truncating to 5 or 10 read depth.

• Bases mapped to the reference, absolute and as a percentage of reference length (ie

normalised)

• Reads mapped to reference, excluding multiple supplementary alignments on the same

reference but including secondary alignments on different references, overall, and restricting

to reads with alignment length ≥200, ≥300, ≥400, or ≥500.

• Reads mapped to a target in a sample as a percentage of the total number of reads in the run,

the total number of reads in the run mapping to any reference or the total number of reads in

the run mapping to references from the target species (the last will be 100% where there only

one reference from a species and only one positive for that species on the run and no false-

positives on the run).

• Reads mapped to a target in a sample as a percentage of the total number of reads in the

sample mapping to references from the target species (100% where there only one reference

from a species and only one positive for that species on the sample).

We excluded the most collinear based on Spearman correlations, leaving eight metrics for detailed

consideration (**Table S2**, **Figure S3**). Area under the receiver operating curves (AUROC) for these

eight ranged from 0.854-0.864 (**Table S2**). We chose individual thresholds for each of these eight

metrics based on Youden's index (**Table S2**) and then calculated the sensitivity and specificity of all

255 combinations of detection based on sequences meeting any one to eight of these metrics (**Table

S4**). The maximum sensitivity of 0.731 was achieved by more than 30 combinations of three metrics

(**Table S4**). We therefore selected a combination which covered three different aspects of sequencing

performance, namely coverage breadth, depth of the mapped reads and the mapped reads as a

percentage of reads mapping to any reference in the run.

Statistical analysis

Detection thresholds for each metric were determined using Youden's index performed on all QC

passing samples in the derivation set. The gold standard was the multiplex PCR results (FilmArray,

Resp-4-Plex, Xpert, **Table 1**). Each sample contributed N observations, one for each of the potential

pathogen targets that could have been detected by the PCR test used (FilmArray 23, Resp-4-

Plex/Xpert 4). For influenza A, FilmArray reports positive/negative overall, and then can report none

or one of three subtypes if positive. These subtypes were only included as targets in analysis if

detected by FilmArray. For sequencing detection, the subtype (H1, H1-2009, H3) was determined by

the highest number of mapped sequencing reads, and Influenza A was counted as positive if any

subtype was positive. ROC analyses for each metric were performed using Python 3.10.4 and

Sklearn[48] v1.1.1. 95% confidence intervals were calculated using binomial proportion with Clopper-

Pearson exact interval using statsmodels[49] v0.15.0.

Data Availability

555   Sequence data are available at the ENA (project number PRJEB102181).

Code Availability

558   https://github.com/oxfordmmm/AD_analysis/tree/v1.0

References

560   1.   Infectious diseases impacting England, 2025 report.

561 2. Stojanovic, Z. *et al.* Advances in diagnostic tools for respiratory tract infections: from

562   tuberculosis to COVID-19 - changing paradigms? *ERJ Open Res.* **8**, 00113–02022 (2022).

563 3. Charlton, C. L. *et al.* Practical Guidance for Clinical Microbiology Laboratories: Viruses

564   Causing Acute Respiratory Tract Infections. *Clin. Microbiol. Rev.* **32**, e00042-18 (2019).

565 4. Chalmers, J. D. The Modern Diagnostic Approach to Community-Acquired Pneumonia in

566   Adults. *Semin. Respir. Crit. Care Med.* **37**, 876–885 (2016).

567 5. Wolf, J. & Daley, A. J. Microbiological aspects of bacterial lower respiratory tract illness

568   in children: typical pathogens. *Paediatr. Respir. Rev.* **8**, 204–210, quiz 210–211 (2007).

569 6. Musher, D. M. & Thorner, A. R. Community-acquired pneumonia. *N. Engl. J. Med.* **371**,

570   1619–1628 (2014).

571 7. UK Health Security Agency. UK Standards for Microbiology Investigations.

572   https://www.rcpath.org/profession/publications/standards-for-microbiology-

573   investigations.html (2025).

574 8. Rytter, H., Jamet, A., Coureuil, M., Charbit, A. & Ramond, E. Which Current and Novel

575   Diagnostic Avenues for Bacterial Respiratory Diseases? *Front. Microbiol.* **11**, 616971

576   (2020).

577 9. Yanagihara, K. The role of molecular diagnosis in acute respiratory tract infection.

578   *Respir. Investig.* **57**, 511 (2019).

579 10. Evans, S. E. *et al.* Nucleic Acid-based Testing for Noninfluenza Viral Pathogens in

580   Adults with Suspected Community-acquired Pneumonia. An Official American Thoracic

581   Society Clinical Practice Guideline. *Am. J. Respir. Crit. Care Med.* **203**, 1070–1087

582   (2021).

583 11. Bouzid, D. *et al.* Added value of rapid respiratory syndromic testing at point of care

584   versus central laboratory testing: a controlled clinical trial. *J. Antimicrob. Chemother.* **76**,

585   iii20–iii27 (2021).

12. Markussen, D. L. *et al.* Diagnostic Stewardship in Community-Acquired Pneumonia With

Syndromic Molecular Testing: A Randomized Clinical Trial. *JAMA Netw. Open* **7**,

e240830 (2024).

13. Del Vecchio, C. *et al.* Impact of antigen test target failure and testing strategies on the

transmission of SARS-CoV-2 variants. *Nat. Commun.* **13**, 5870 (2022).

14. Blais, J. *et al.* Risk of Misdiagnosis Due to Allele Dropout and False-Positive PCR

Artifacts in Molecular Diagnostics: Analysis of 30,769 Genotypes. *J. Mol. Diagn. JMD*

17, 505–514 (2015).

15. Castañeda-Mogollón, D. *et al.* A metagenomics workflow for SARS-CoV-2

identification, co-pathogen detection, and overall diversity. *J. Clin. Virol. Off. Publ. Pan*

Am. Soc. Clin. Virol. **145**, 105025 (2021).

16. Heitz, M. *et al.* Metagenomics for the microbiological diagnosis of hospital-acquired

pneumonia and ventilator-associated pneumonia (HAP/VAP) in intensive care unit (ICU):

a proof-of-concept study. *Respir. Res.* **24**, 285 (2023).

17. Charalampous, T. *et al.* Routine Metagenomics Service for ICU Patients with Respiratory

Infection. *Am. J. Respir. Crit. Care Med.* **209**, 164–174 (2024).

18. Hsu, W.-Y. *et al.* Performance of a hybrid capture-based target enrichment next-

generation sequencing for the identification of respiratory pathogens and resistance-

associated genes in patients with severe pneumonia. *Microbiol. Spectr.* **13**, e0213024

(2025).

19. Gan, M. *et al.* Antimicrobial resistance prediction by clinical metagenomics in pediatric

severe pneumonia patients. *Ann. Clin. Microbiol. Antimicrob.* **23**, 33 (2024).

20. Chen, H. *et al.* Assessment and clinical utility of metagenomic next-generation

sequencing for suspected lower respiratory tract infections. *Eur. J. Med. Res.* **29**, 213

(2024).

21. Alcolea-Medina, A. *et al.* Rapid pan-microbial metagenomics for pathogen detection and

personalised therapy in the intensive care unit: a single-centre prospective observational

study. *Lancet Microbe* **6**, (2025).

22. Alcolea-Medina, A. *et al.* Unified metagenomic method for rapid detection of

microorganisms in clinical samples. *Commun. Med.* **4**, 135 (2024).

23. Gauthier, N. P. G. *et al.* Validation of an Automated, End-to-End Metagenomic

Sequencing Assay for Agnostic Detection of Respiratory Viruses. *J. Infect. Dis.* **230**,

e1245–e1253 (2024).

24. Tan, J. K. *et al.* Laboratory validation of a clinical metagenomic next-generation

sequencing assay for respiratory virus detection and discovery. *Nat. Commun.* **15**, 9016

(2024).

25. Yin, Y. *et al.* Enhancing lower respiratory tract infection diagnosis: implementation and

clinical assessment of multiplex PCR-based and hybrid capture-based targeted next-

generation sequencing. *EBioMedicine* **107**, 105307 (2024).

26. Guo, Y. *et al.* A dual-process of targeted and unbiased Nanopore sequencing enables

accurate and rapid diagnosis of lower respiratory infections. *EBioMedicine* **98**, 104858

(2023).

27. Diao, Z. *et al.* Assessing the Quality of Metagenomic Next-Generation Sequencing for

Pathogen Detection in Lower Respiratory Infections. *Clin. Chem.* **69**, 1038–1049 (2023).

28. Torres Montaguth, O. E., Buddle, S., Morfopoulou, S. & Breuer, J. Clinical

metagenomics for diagnosis and surveillance of viral pathogens. *Nat. Rev. Microbiol.* 1–

15 (2025) doi:10.1038/s41579-025-01223-5.

29. Marić, J., Križanović, K., Riondet, S., Nagarajan, N. & Šikić, M. Comparative analysis of

metagenomic classifiers for long-read sequencing datasets. *BMC Bioinformatics* **25**, 15

(2024).

30. Cane, J. *et al.* Nanopore sequencing of influenza A and B in Oxfordshire and the United

Kingdom, 2022–23. *J. Infect.* **88**, 106164 (2024).

31. Street, T. L. *et al.* Nanopore adaptive sampling for bacterial identification from

periprosthetic joint replacement tissue. *Microb. Genomics* **11**, (2025).

32. Wright, P. F. *et al.* Comparison of Results of Detection of Rhinovirus by PCR and Viral

Culture in Human Nasal Wash Specimens from Subjects with and without Clinical

Symptoms of Respiratory Illness. *J. Clin. Microbiol.* **45**, 2126–2129 (2007).

33. Venkatesan, P. UK launch metagenomic pathogen surveillance programme. *Lancet*

Microbe **6**, (2025).

34. Bouzid, D. *et al.* Agreement of respiratory viruses' detection between nasopharyngeal

swab and bronchoalveolar lavage in adults admitted for pneumonia: a retrospective study.

Clin. Microbiol. Infect. **29**, 942.e1-942.e6 (2023).

35. Lin, C. *et al.* Comparison of throat swabs and sputum specimens for viral nucleic acid

detection in 52 cases of novel coronavirus (SARS-Cov-2)-infected pneumonia (COVID-

19). *Clin. Chem. Lab. Med.* **58**, 1089–1094 (2020).

36. Mei, F. *et al.* Diagnostic Role of Bronchoalveolar Lavage in Patients with Suspected

SARS-CoV-2 Pneumonia and Negative Upper Respiratory Tract Swab: A Systematic

Review and Meta-Analysis. *J. Clin. Med.* **11**, 4656 (2022).

37. Wood, D. E., Lu, J. & Langmead, B. Improved metagenomic analysis with Kraken 2.

Genome Biol. **20**, 257 (2019).

38. Shaw, J. & Yu, Y. W. Rapid species-level metagenome profiling and containment

estimation with sylph. *Nat. Biotechnol.* **43**, 1348–1359 (2025).

39. Ameni, G. *et al.* A Narrative Review on the Pandemic Zoonotic RNA Virus Infections

Occurred During the Last 25 Years. *J. Epidemiol. Glob. Health* **14**, 1397–1412 (2024).

40. Carrasco-Hernandez, R., Jácome, R., López Vidal, Y. & Ponce de León, S. Are RNA Viruses Candidate Agents for the Next Global Pandemic? A Review. *ILAR J.* **58**, 343–358 (2017).

41. Garcia-Blanco, M. A., Ooi, E. E. & Sessions, O. M. RNA Viruses, Pandemics and Anticipatory Preparedness. *Viruses* **14**, 2176 (2022).

42. K, L. *et al.* Metagenomic Nanopore Sequencing of Influenza Virus Direct from Clinical Respiratory Samples. *J. Clin. Microbiol.* **58**, (2019).

43. Constantinides, B., Lees, J. & Crook, D. W. Deacon: fast sequence filtering and contaminant depletion. 2025.06.09.658732 Preprint at https://doi.org/10.1101/2025.06.09.658732 (2025).

44. Shen, W., Sipos, B. & Zhao, L. SeqKit2: A Swiss army knife for sequence and alignment processing. *iMeta* **3**, e191 (2024).

45. BLAST+: architecture and applications | BMC Bioinformatics | Full Text. https://bmcbioinformatics.biomedcentral.com/articles/10.1186/1471-2105-10-421.

46. Li, H. Minimap2: pairwise alignment for nucleotide sequences. *Bioinformatics* **34**, 3094–3100 (2018).

47. Danecek, P. *et al.* Twelve years of SAMtools and BCFtools. *GigaScience* **10**, giab008 (2021).

48. Pedregosa, F. *et al.* Scikit-learn: Machine Learning in Python. *J. Mach. Learn. Res.* **12**, 2825–2830 (2011).

49. Seabold, S. & Perktold, J. statsmodels: Econometric and statistical modeling with python. in *9th Python in Science Conference* (2010).

Acknowledgements (optional)

This project was funded by the NIHR Biomedical Research Centre, Oxford, and supported by the

NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial

Resistance at Oxford University in partnership with the UK Health Security Agency (UKHSA)

(NIHR207397). The views expressed are those of the authors and not necessarily those of the NHS,

the NIHR, the Department of Health and Social Care or UKHSA. ASW is an NIHR Senior

Investigator. For the purpose of Open Access, the author has applied a CC BY public copyright

licence to any Author Accepted Manuscript (AAM) version arising.

Ethics declarations

693   The use of surplus material from respiratory samples processed by the Oxford University Hospitals

694   NHS Foundation Trust Clinical Microbiology laboratory, and use of de-identified patient information

695   from these samples, without patient-level consent, was approved by the Queens Square NHS Research

696   Ethics Committee (REC), London, reference 17/LO/1420, as part of work on the development of rapid

697   diagnostics.

Competing interests

700   The authors have no competing interests to declare.

702 **Table 1 Characteristics of patient samples (nose and throat swabs) and sequences in derivation**
703 **and validation sets**

704 **(a)**

	Derivation set samples (N=38)	Derivation set sequences† (N=104)	Derivation set sequences QC pass†† (N=61)	Validation set samples/ sequences (N=344)	Validation set samples/ sequences QC pass†† (N=273)
Original test by (n (%))					
Xpert Xpress CoV-2/Flu/RSV plus*	2 (5%)	4 (4%)	4 (7%)	9 (3%) (2-°,7+)	9 (3%) (2-°,7+)
Alinity Resp-4-Plex*	6‡ (16%)	18‡ (17%)	8‡ (13%)	136 (40%) (0-,136+)	102 (37%) (0-,102+)
BIOFIRE FilmArray Respiratory 2.1**	31‡ (82%)	85‡ (82%)	51‡ (84%)	199 (58%) (45-,154+)	162 (59%) (36-,126+)
Number of pathogen targets detected‡‡, n (%)					
0	0	0	0	47 (14%)	38 (14%)
1	34 (89%)	94 (90%)	55 (90%)	270 (78%)	212 (78%)
2	4 (11%)	10 (10%)	6 (10%)	25 (7%)	21 (8%)
3	0	0	0	2 (1%)	2 (1%)
Total pathogen targets detected	42	114	67	326	260
Thousand reads generated	-	92 (69-127)	89 (68-108)	115 (81-151)	115 (82-146)
Median read length	-	292 (278-308)	290 (275-300)	270 (246-292)	276 (256-295)
N50	-	428 (375-469)	448 (382-473)	386 (336-429)	393 (348-432)
Read PHRED quality	-	10.9 (10.0-12.3)	10.5 (9.9-11.2)	11.4 (11.0-11.7)	11.4 (11.1-11.7)
Any target pathogen reads identified, n (%) - median (IQR) reads if >0	-	77 (74%) 35 (5-166)	49 (80%) 18 (5-98)	230 (67%) 6 (2-151)	191 (70%) 8 (2-188)
Any gold standard (target) pathogen reads identified, n (%) – median (IQR) reads if >0	-	64 (62%) 70 (6-2817)	45 (74%) 46 (6-135)	198 (58%) 44 (4-514)	162 (59%) 58 (4-603)

* tests for influenza A/B, RSV and SARS-CoV-2 (**Table S1**).
** tests for adenovirus, coronaviruses (229E, HKU1, NL63, OC43, SARS-CoV-2, MERS-CoV),
human metapneumovirus, human rhino/enterovirus, influenza viruses (including subtypes influenza A,
A/H1, A/H3, A/H1-2009), influenza B virus, parainfluenza viruses (1-4), respiratory syncytial virus,
Bordatella parapertussis, *Bordetella pertussis*, *Chlamydia pneumoniae* and *Mycoplasma pneumoniae*
(**Table S1**).
† Original derivation samples were split and sequenced multiple times. Some sequenced samples
included pooled samples tested with multiple platforms, see ‡. For the validation set each sample was
sequenced once only.
†† Samples that passed run, batch and sample internal controls, see **Table 2**.
‡ One derivation set sample was pooled and tested using both Resp-4-plex and FilmArray; this was
sequenced 3 times.
‡‡ Includes influenza subtypes as separate pathogen targets.
° Included in error
719
720

721 **(b)**

	Validation set samples/ sequences (N=344)	Validation set samples/ sequences QC pass†† (N=273)
Patient age (years)	48 (3-70) n=342*	38 (2-68) n=271*
<1	46 (13%)	37 (14%)
1-12	70 (20%)	65 (24%)
13-49	56 (16%)	45 (17%)
50-70	86 (25%)	66 (24%)
71-84	58 (17%)	39 (14%)
85+	26 (8%)	19 (7%)
Male	176 (51%) n=342*	141 (52%) n=271*
Location where sample taken		
Haematology or oncology	103 (30%)	83 (30%)
Other inpatient adult ward	77 (22%)	53 (19%)
Other inpatient paediatric ward	38 (11%)	30 (11%)
Ambulatory or emergency department	92 (27%)	76 (28%)
Critical care	19 (6%)	18 (7%)
Community	13 (4%)	11 (4%)
Trial	2 (1%)	2 (1%)
Days between collection and extraction date	5 (3-6)	5 (3-6)
Copy number (Cn) (Alinity)	22.5 (19.7-25.3)	22.9 (20.3-25.5)
Cycle threshold (Ct) (Xpert)	19.5 (18.8-22.1)	19.5 (18.8-22.1)
Total pathogens detected by routine testing	326	260
Study qPCR performed**	306 (94%)	244 (94%)
Study qPCR run, but Ct undetermined (>40) (% of routine testing targets with qPCR)	68 (22%)	50 (20%)
Study qPCR run, Ct determined (<40) (% of routine testing targets with qPCR) - Median (IQR) Ct	238 (78%) 30.2 (IQR: 27.2-33.7)	194 (80%) 30.0 (IQR: 27.2-33.9)

722   * missing values from anonymised trial samples. Percentages of non-missing values.
723   ** DNA target or multiple pathogens identified on routine testing and insufficient sample to run qPCR
724   for all (see **Methods**)
725
726   Note: showing n (%) or median (IQR). QC=quality control. See **Figure S1** for run characteristics.

Table 2 Quality check, controls and pathogen detection thresholds for CMg workflow

Type	Threshold for failure (any)	Applied to	Rationale
Control (original prespecified before validation study)			
Run sequencing	<400 Mb data	Sequencing run (two batches of 16 samples plus controls)	Minimum level of sequencing data acquisition given variability across runs (**Figure S1**)
Sample sequencing	<25,000 reads	Each sample (unique barcode)	Minimum level of sequencing data acquisition given variability across samples. Minimum read number ensures sample QC is not biased by few very long reads (**Figure S1**)
Batch PCR negative control	≥2 reads mapped to any of the four positive spikes* or any target pathogen not failing (i.e. passing) main or ratio positivity criteria below	Negative control on each batch	Negative (no template) control included with all samples undergoing SISPA PCR in a batch. Detecting target amplification in this control indicates cross contamination.
Batch positive amplification control	<2 reads mapped to 2 or 3 of the 3 amplification controls	Positive control on each batch	Control with only 3 RNA virus spikes included in double stranded (ds) cDNA synthesis and SISPA amplification process for a batch of samples. Failure to detect the virus spike indicates these processes have failed across the batch.
Batch positive amplification control	MS2 or any target pathogen not failing (i.e. passing) main or ratio positivity criteria below	Positive control on each batch	Control with only 3 RNA virus spikes included in ds cDNA synthesis and SISPA amplification process for a batch of samples. Detecting MS2 or a target pathogen indicates cross-contamination.
Internal extraction, cDNA synthesis and SISPA control	<2 reads mapped to MS2**	Each sample	MS2 is added prior to RNA extraction. Failure to detect in a sample indicates that RNA extraction and/or subsequent amplification has failed within the sample
Internal cDNA synthesis and SISPA control	<2 reads mapped to 2 or 3 of the 3 amplification controls	Each sample	Three RNA virus spikes added prior to ds cDNA synthesis and downstream amplification. Failure to detect indicates these processes have failed within the sample.
Positivity to a target pathogen (original pre-specified before validation study)			
Barcode crossover	<2 reads mapped to a target pathogen	Each sample	Reduce impact of barcode crossover, **Figure S2**
Main criteria	Area under the genome truncated at 10 <0.003 AND coverage at depth 1 <0.25% AND sample reads as a percentage of all references <0.006%	Each sample	Combination of three metrics performance with high sensitivity and AUROC in derivation set, reducing potential impact of kitome and sample contamination observed in previous multiplexed sequencing studies.

Type	Threshold for failure (any)	Applied to	Rationale
Ratio criteria	Ratio sample reads as a percentage of all references / area under the genome truncated at 10<0.1	Each sample	Excluded 23 false-positives in the full derivation set (**Figure 3**)
Positivity to a target pathogen (alternative exploratory after validation study)			
Barcode crossover	<2 reads mapped to a target pathogen	Each sample	Reduce impact of barcode crossover, **Figure S2**
Main criteria	Sample reads as a percentage of reads mapping to all target references <0.037%	Each sample	Single metric optimising sensitivity, specificity and AUROC and sensitivity in derivation set

* MS2 and internal viral amplification controls (Zika virus, murine respirovirus and orthoreovirus). Each sequencing run included 32 samples on a single flow cell. Samples were extracted and amplified in batches of 16 samples plus batch controls, and two batches included in a run.

** Quality check included for the validation set only due to inconsistent performance of the MS2 stock in the derivation experiments.

Note: All run, batch individual sample quality check criteria had to pass in order to have pathogen reported as detected by sequencing; target pathogen declared present if all positivity criteria met. See **Figure 4** for a summary of the combinations of criteria passed and failed.

Table 3 Sensitivity and specificity of different criteria for positivity in validation set

Analysis	Sensitivity (per target)	Pathogen targets not detected on qPCR*	Sensitivity in true-positive targets detected by qPCR	Sensitivity in true-positive targets with study qPCR Ct < 35	Pathogen targets with 0 mapped reads	Sensitivity in true-positive targets with >0 mapped reads	Sensitivity (per sample)	Specificity (per target)	False-positive detections	Specificity (per sample, excluding true positive targets)	Specificity (per negative sample)
Derivation criteria (**Table 2**)	51% [45-57%] (133/260)	66	66% [59-73%] (129/194)	73% [65-80%] (116/159)	89	78% [71-84%] (133/171)	55% [48-61%] (129/235)	99.8%[99.6%-99.9%] (3901/3910)	9	96.7%[93.8%-98.5%] (264/273)	94.7%[82.3%-99.4%] (36/38)
Replace main and ratio criteria with detection if the number of reads mapping to the target reference as a percentage of the number of reads mapping to the same reference in the run >0.037% (alternative criteria)	58% [52-64%] (159/274)	68	75% [68-81%] (154/206)	83% [76-88%] (140/169)	89	86% [80-91%] (159/185)	61% [55-67%] (152/249)	99.9%[99.8%-100.0%] (4015/4017)	2	99.3%[97.5%-99.9%] (287/289)	100%[91.2%-100%] (40/40)
Alternative criteria, only RNA pathogens	61% [55-67%] (159/260)	54	75% [68-81%] (154/206)	83% [76-88%] (140/169)	75	86% [80-91%] (159/185)	61% [55-67%] (152/249)	99.9%[99.8%-100.0%] (3204/3206)	2	99.3%[97.5%-99.9%] (287/289)	100%[91.2%-100%] (40/40)
Alternative criteria, only RNA pathogens other than rhinovirus/enterovirus	70% [63-76%] (144/207)	47	87% [81-92%] (139/160)	95% [90-98%] (125/131)	46	89% [84-94%] (144/161)	56% [50-62%] (140/249)	99.9%[99.8%-100.0%] (3092/3094)	2	99.3%[97.5%-99.9%] (287/289)	100%[91.2%-100%] (40/40)

* reflecting loss of genomic material during processing or study qPCR not conducted due to insufficient material remaining, see **Table 1**.

Figure 1 Clinical metagenomic workflow overview

Figure 2 Pathogens identified (A, B) and not identified (C,D) on routine diagnostic testing in (A, C) derivation and (B, D) validation sets. Each sample could be positive for multiple pathogens, see **Table 1**.

Figure 3 Batch control (A, B) and positive control (C, D) passed per sample and target detection (E, F) criteria passed for (A, C, E) derivation and (B, D, F) validation sets. Red indicates passed and black failed. RNA from murine respirovirus, orthoreovirus and Zika virus were spiked as cDNA synthesis and SISPA controls, MS2 phage was spiked as an extraction, cDNA synthesis and SISPA control. Within the derivation set MS2 was not required to pass QC due to poor performance of the laboratory MS2 stock; in both validation and derivation only detection of 2/3 virus spikes was required to pass QC.

Figure 4 Positivity ratio criteria as developed in the derivation set (A,C) and tested in the validation set (B,D) Showing samples which passed sample QC thresholds (**Table 2**) in panels A, B and samples which failed sample QC thresholds in panels C, D. The sample QC pass (panels A, B) includes samples that failed batch controls, to provide context for barcode bleedover. In panel A classification of gold standard PCR-positives in the derivation set as true or false was based only on the number of reads and the main criteria (**Table 2**), ie did not include the ratio criteria shown by the red line, which was developed from the derivation set. In panel B, the classification of gold standard positives in the validation set does include the ratio criteria as shown by the red line. Individual thresholds shown in grey dashed lines.

Figure 5 Validation set sample flow

Figure 6 Pathogen-specific detections (A) and sensitivity (if >20 gold-standard detections) (B) in the derivation and validation sets. 95% confidence intervals calculated using Clopper-Pearson interval based on Beta distribution.

Figure 7 Association between number of mapped reads and Cn/Ct values from original assay (A) or study qPCR (B)

(A)

(B)